Centro de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS)
Centro singular
![Foto de Centro de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS)](/img/noimage.png)
![Foto de GlaxoSmithKline (United Kingdom)](/img/noimage_org.png)
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublicacións en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (6)
2018
-
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
The Lancet, Vol. 392, Núm. 10157, pp. 1519-1529
2016
-
Open PHACTS computational protocols for: In silico target validation of cellular phenotypic screens: Knowing the knowns
MedChemComm, Vol. 7, Núm. 6, pp. 1237-1244
2014
2013
-
Scientific competency questions as the basis for semantically enriched open pharmacological space development
Drug Discovery Today, Vol. 18, Núm. 17-18, pp. 843-852
-
Scientific requirements for the next-generation semantic web-based chemogenomics and systems chemical biology molecular information system OPS
Computational Chemogenomics (Pan Stanford Publishing Pte. Ltd.), pp. 213-242
2002
-
Oxidative damage and phospholipid fatty acyl composition in skeletal muscle mitochondria from mice underexpressing or overexpressing uncoupling protein 3
Biochemical Journal, Vol. 368, Núm. 2, pp. 597-603